कंपनी का अवलोकन
Nyxoah SA is a medical technology enterprise dedicated to developing and commercializing therapeutic solutions designed to treat obstructive sleep apnea (OSA). The company's primary offering includes the Genio system, which functions as a patient-centric, minimally invasive hypoglossal neurostimulation therapy capable of addressing moderate to severe cases of the condition. This organization operates within the Healthcare sector, specifically classified under the Medical Instruments & Supplies industry, where it focuses on advanced medical device innovation rather than pharmaceuticals. Nyxoah SA currently holds a market capitalization of $123.13M and generates annual revenue of $10.02M, while the specific employee count is listed as unavailable in current records. These financial dimensions indicate that the company operates as a smaller-cap entity within the broader medical technology landscape, suggesting a niche position focused on specialized neurostimulation technologies rather than mass-market volume sales. The relatively modest market cap relative to the healthcare sector's giants implies that investors are pricing the stock based on future potential and regulatory milestones rather than established historical profitability.
वित्तीय स्वास्थ्य
The company reports a trailing twelve-month (TTM) revenue of $10.02M, yet it simultaneously records a significant net loss of $-90,085,000 and an EBITDA of $-82,369,000. The substantial disparity between the modest revenue figure and the large negative net income reveals a cost structure characterized by high operating expenses or significant one-time charges that outweigh current sales generation. While the Free Cash Flow metric is listed as N/A, the available cash balance stands at $48.00M, which provides a critical buffer for ongoing research and development expenditures despite the current lack of positive cash flow generation. The gross margin stands at 63.1%, indicating that the company retains a healthy portion of revenue after accounting for the direct costs of producing its medical devices. However, the operating margin is severely negative at -330.1%, and the profit margin is recorded as 0.0%, signaling that overhead costs and operational inefficiencies are currently consuming all generated profits. In terms of solvency, the company holds $48.00M in cash against $42.08M in debt, resulting in a debt-to-equity ratio of 85.64. Although the absolute debt level is lower than the cash reserve, the elevated debt-to-equity ratio suggests a leveraged balance sheet that relies heavily on equity financing or asset appreciation to cover obligations. The current ratio of 1.25 indicates that the company possesses sufficient current assets to cover its short-term liabilities, reflecting a moderate level of short-term liquidity. Furthermore, the Return on Equity is -111.0% and the Return on Assets is -37.7%, metrics that collectively reveal that management is currently generating negative returns on the capital invested by shareholders and the company's asset base.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is listed as N/A due to negative earnings, while the forward P/E is recorded at -1.85, implying that the market expects earnings to remain negative or that valuation models are relying on alternative inputs given the lack of profitability. The price-to-book ratio is 2.17, which indicates that the stock is trading at a premium of over twice its book value, suggesting that investors are pricing in significant future growth potential or intangible asset value rather than current tangible assets. Additionally, the price-to-sales ratio stands at 12.29 and the EV/EBITDA is -1.42, figures that suggest the market is valuing the company primarily on its revenue generation capabilities and strategic pipeline rather than traditional earnings multiples. The stock's 52-week trading range spans from a low of $2.77 to a high of $11.87, placing the current valuation within a wide volatility band relative to this historical performance envelope. The beta value of 0.62 suggests that the stock exhibits lower volatility than the broader market, moving at roughly 38% less intensity than the market average during periods of fluctuation. This low beta characteristic is notable for a healthcare stock, indicating that price movements may be less correlated with general market sentiment and more driven by specific industry or company-specific developments.
Growth & Income
Nyxoah SA demonstrates a revenue growth rate of 346.9% year-over-year, while earnings growth is listed as N/A due to the company's continued net losses. The absence of positive earnings growth relative to revenue highlights a stage of business where top-line expansion is occurring, but profitability has not yet been achieved. Since the company does not pay dividends, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, all available cash is theoretically available for reinvestment into growth initiatives rather than distribution to shareholders. This reinvestment strategy is typical for early-stage medical technology firms that prioritize product development and market penetration over returning capital to investors. The overall growth and income profile is defined by rapid revenue expansion coupled with significant cash burn, resulting in a financial structure that relies on external capital markets or cash reserves to fund operations until operational profitability is realized. The company's financial trajectory suggests a high-risk, high-reward scenario where the 346.9% revenue surge must be sustained to eventually convert the negative operating margins into positive earnings.